SynthesisThe British journal of dermatology2020

Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).

A Wollenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.